Science at Sanofi

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

We are pleased to share with you information on ‘Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis,’ together with the ‘Guidelines of Care for the Management of Atopic Dermatitis in Pediatric Patients.’ We believe these publications may be of interest to you.

This email highlights key evidence regarding dupilumab, including its long-term safety and efficacy profile in infants and young children with atopic dermatitis. It also presents current guideline recommendations, which strongly support the use of dupilumab in children aged 6 months and older with moderate-to-severe atopic dermatitis.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Catch up on EADV 2026 poster highlights: real-world dupilumab data in atopic dermatitis, bullous pemphigoid and prurigo nodularis. For healthcare professionals.

Explores the connections between Type 2 inflammatory diseases and the opportunities to improve patient outcomes through earlier, targeted intervention

Access ERS 2026 Congress highlights on severe asthma, COPD, and biologic therapies. Real-world evidence and clinical insights for HCPs

Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.

Discover the latest breakthroughs in pediatric infectious diseases, focusing on Pertussis, Polio and Hib protection.

T2D patients with uncontrolled on Basal insulin switching to iGlarLixi

T2D patients with uncontrolled on Premixed insulin

Uncontrolled on GLP-1 RA:​ 
What’s the next step?​
by Assoc. Prof. Taweesak Wannachalee

When OADs are not enough: Choosing Gla-300 for stability by Dr. Kampantong Tangweerapong

T2D patients with post-OADs, high A1C and PPG by Dr. Chonpiti Siriwan

LMWH in Acute Coronary Syndromes by DR.PURICH SURUNCHUPAKORN.

Watch now to gain clinical insights from Dr. Wiwat Rodprasert

Don’t wait—see how early treatment changes outcomes.